Valvular Heart Disease in Antiphospholipid Syndrome

  • Stéphane Zuily
  • Olivier Huttin
  • Shirine Mohamed
  • Pierre-Yves Marie
  • Christine Selton-Suty
  • Denis Wahl
ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)
Part of the following topical collections:
  1. Topical Collection on Antiphospholipid Syndrome

Abstract

Heart valve disease (HVD) is the most frequent cardiac manifestation in patients with antiphospholipid syndrome (APS), with prevalence of 30 %. The definition is based on the presence of thickening or vegetation of the valves (mainly mitral and aortic) as described by Libman and Sacks for patients with systemic lupus erythematosus (SLE). Transthoracic and/or transoesophageal echocardiography (TTE and TEE, respectively) enable early and accurate diagnosis and help avoid misdiagnosis as rheumatic valve disease. The presence of antiphospholipid antibodies (aPL) in SLE patients is associated with a threefold greater risk of HVD, confirming the crucial importance of these antibodies in the pathogenic process, leading to thrombotic manifestations on valves because of hypercoagulability. Natural history is characterized by worsening of HVD over time with an increased risk for stroke. APS patients undergoing valve-replacement surgery are at high risk of thrombotic and bleeding complications. Thus aPL-associated HVD has affects clinical management of APS patients.

Keywords

Antiphospholipid syndrome Antiphospholipid antibodies Systemic lupus erythematosus Heart valve disease Libman–Sacks endocarditis Non-bacterial endocarditis Mitral valve Aortic valve Valve thickening Valve dysfunction Rheumatic disease Trans-thoracic echocardiography Trans-oesophageal echocardiography Thrombo-embolic event Stroke Anticoagulant Antiplatelet therapy Cardiac surgery Thrombosis Bleeding 

Notes

Conflicts of interest

Stéphane Zuily declares that he has no conflict of interest.

Olivier Huttin declares that he has no conflict of interest.

Shirine Mohamed declares that she has no conflict of interest.

Pierre-Yves Marie declares that he has no conflict of interest.

Christine Selton-Suty declares that she has no conflict of interest.

Denis Wahl declares that he has no conflict of interest.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.PubMedCrossRefGoogle Scholar
  2. 2.
    Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Lakos G, Favaloro EJ, Harris EN, et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012;64:1–10.PubMedCrossRefGoogle Scholar
  4. 4.
    • Cervera R, Tektonidou MG, Espinosa G, et al. Task force on catastrophic Antiphospholipid Syndrome (APS) and non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20:165–73. This recent consensus report reviewed a large number of studies performed on patients with aPL and HVD and gave recommendations for management of these patients.PubMedCrossRefGoogle Scholar
  5. 5.
    Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.PubMedCrossRefGoogle Scholar
  6. 6.
    Menard GE. Establishing the diagnosis of Libman–Sacks endocarditis in systemic lupus erythematosus. J Gen Intern Med. 2008;23:883–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Taguchi S, Hashimoto K, Sakamoto Y, Okuyama H, Ishii S. A case of mitral valve plasty for Libman–Sacks endocarditis mimicking a cardiac tumor. J Thorac Cardiovasc Surg. 2006;132:1465–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Ford SE, Lillicrap D, Brunet D, Ford P. Thrombotic endocarditis and lupus anticoagulant. A pathogenetic possibility for idiopathic ‘rheumatic type’ valvular heart disease. Arch Pathol Lab Med. 1989;113:350–3.PubMedGoogle Scholar
  9. 9.
    Espinola-Zavaleta N, Amigo MC, Vargas-Barron J, et al. Two- and three-dimensional echocardiography in primary antiphospholipid syndrome: misdiagnosis as rheumatic valve disease. Lupus. 2001;10:511–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924;33:701–37.CrossRefGoogle Scholar
  11. 11.
    Eiken PW, Edwards WD, Tazelaar HD, McBane RD, Zehr KJ. Surgical pathology of nonbacterial thrombotic endocarditis in 30 patients, 1985–2000. Mayo Clin Proc. 2001;76:1204–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Piette JC, Amoura Z, Papo T. Valvular heart disease and systemic lupus erythematosus. N Engl J Med. 1997;336:1324. author reply 1324–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54:3918–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Morelli S, Bernardo ML, Viganego F, et al. Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus. 2003;12:805–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Perez-Villa F, Font J, Azqueta M, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum. 2005;53:460–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol. 2005;95:1441–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology. 2007;108:331–7.PubMedCrossRefGoogle Scholar
  18. 18.
    •• Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124:215–24. This meta-analysis of all available echocardiographic studies clearly demonstrated that for SLE patients with aPL, compared with those without, the risk of HVD, including Libman–Sacks endocarditis, was increased threefold.PubMedCrossRefGoogle Scholar
  19. 19.
    Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke. 2005;36:592–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Turiel M, Muzzupappa S, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus. 2000;9:406–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Turiel M, Sarzi-Puttini P, Peretti R, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol. 2005;96:574–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol. 2004;31:2402–7.PubMedGoogle Scholar
  23. 23.
    Petri MA. Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease. J Rheumatol. 2004;31:2329–30.PubMedGoogle Scholar
  24. 24.
    Ziporen L, Goldberg I, Arad M, et al. Libman–Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996;5:196–205.PubMedCrossRefGoogle Scholar
  25. 25.
    Blank M, Shani A, Goldberg I, et al. Libman–Sacks endocarditis associated with antiphospholipid syndrome and infection. Thromb Res. 2004;114:589–92.PubMedCrossRefGoogle Scholar
  26. 26.
    Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Revisiting Libman–Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol. 2009;36:126–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Lecompte T, Wahl D, Perret-Guillaume C, Hemker HC, Lacolley P, Regnault V. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica. 2007;92:714–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Liestol S, Sandset PM, Mowinckel MC, Wisloff F. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost. 2007;5:2204–10.PubMedCrossRefGoogle Scholar
  29. 29.
    Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579–87.PubMedCrossRefGoogle Scholar
  30. 30.
    Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman–Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007;120:636–42.PubMedCrossRefGoogle Scholar
  31. 31.
    Amoroso A, Cacciapaglia F, De Castro S, et al. The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement. Clin Exp Rheumatol. 2006;24:287–94.PubMedGoogle Scholar
  32. 32.
    Balada E, Ordi-Ros J, Paredes F, Villarreal J, Mauri M, Vilardell-Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol. 2001;30:235–41.PubMedCrossRefGoogle Scholar
  33. 33.
    • Pardos-Gea J, Ordi-Ros J, Avegliano G, et al. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus. 2010;19:575–82. This study reports results from a relatively small cohort with a long follow-up and reports the incidence of new valvular involvement over time.PubMedCrossRefGoogle Scholar
  34. 34.
    •• Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428–32. This study reported epidemiologic data of the largest multicenter cohort of APS patients ever published and reported results for HVD. However, because of the multicentre design the diagnostic workout was heterogeneous.PubMedCrossRefGoogle Scholar
  35. 35.
    Tektonidou MG, Kampolis CF, Moyssakis I, et al. Myocardial dysfunction and valvulopathy worsens with time in patients with antiphospholipid syndrome: a 10-year follow-up study. [Abstract 1738]. Presented at the American College of Rheumatology / ARHP Annual Meeting. Washington, USA; November 10–14, 2012.Google Scholar
  36. 36.
    Vinales KL, Gopalan RS, Lanza LA, Lester SJ, Chaliki HP. Unusual case of nonbacterial thrombotic endocarditis attributable to primary antiphospholipid syndrome. Circulation. 2010;122:e459–60.PubMedCrossRefGoogle Scholar
  37. 37.
    Deo SV, Park SJ. Primary antiphospholipid antibody syndrome and Libmann–Sachs endocarditis. Mayo Clin Proc. 2011;86:929.PubMedCrossRefGoogle Scholar
  38. 38.
    Shroff H, Benenstein R, Freedberg R, Mehl S, Saric M. Mitral valve Libman–Sacks endocarditis visualized by real time three-dimensional transesophageal echocardiography. Echocardiogr. 2012;29:E100–1.CrossRefGoogle Scholar
  39. 39.
    Roldan CA. Diagnostic value of transesophageal echocardiography in Libman–Sacks endocarditis. Minerva Cardioangiol. 2009;57:467–81.PubMedGoogle Scholar
  40. 40.
    Schneider C, Bahlmann E, Antz M, et al. Images in cardiovascular medicine. Unusual manifestation of Libman–Sacks endocarditis in systemic lupus erythematosus. Circulation. 2003;107:e202–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Roldan CA, Gelgand EA, Qualls CR, Sibbitt Jr WL. Valvular heart disease is associated with nonfocal neuropsychiatric systemic lupus erythematosus. J Clin Rheumatol. 2006;12:3–10.PubMedCrossRefGoogle Scholar
  42. 42.
    Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1490–3.PubMedCrossRefGoogle Scholar
  43. 43.
    Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum. 1997;27:27–35.PubMedCrossRefGoogle Scholar
  44. 44.
    Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003;12:518–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg. 2008;33:168–81.PubMedCrossRefGoogle Scholar
  46. 46.
    •• Erdozain JG, Ruiz-Irastorza G, Segura MI, et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res (Hoboken). 2012;64:1256–60. In this retrospective study of patients undergoing cardiac valve surgery, Erdozain et al. revealed the very high-risk of these procedures for patients with APS in terms of thrombotic and bleeding complications.Google Scholar
  47. 47.
    Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127:414–20.PubMedCrossRefGoogle Scholar
  48. 48.
    Colli A, Mestres CA, Espinosa G, et al. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg. 2010;37:154–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Hegde VA, Vivas Y, Shah H, et al. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome–a case-series. Heart Lung Circ. 2007;16:423–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Unger P, Plein D, Pradier O, LeClerc JL. Thrombosis of aortic valve homograft associated with lupus anticoagulant antibodies. Ann Thorac Surg. 2004;77:312–4.PubMedCrossRefGoogle Scholar
  51. 51.
    Saito S, Ikeguchi H, Yamamoto H, Koike A, Yamaguchi K, Takeuchi E. Does antiphospholipid antibody syndrome affect bioprosthetic heart valve? midterm echocardiographic report. Jpn J Thorac Cardiovasc Surg. 2005;53:36–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Hogan WJ, McBane RD, Santrach PJ, et al. Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin Proc. 2000;75:971–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford). 2000;39:421–6.CrossRefGoogle Scholar
  54. 54.
    Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366:1705–15.PubMedCrossRefGoogle Scholar
  55. 55.
    Maisano F, La Canna G, Colombo A, Alfieri O. The evolution from surgery to percutaneous mitral valve interventions: the role of the edge-to-edge technique. J Am Coll Cardiol. 2011;58:2174–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Stéphane Zuily
    • 1
    • 2
    • 3
    • 6
  • Olivier Huttin
    • 4
    • 7
  • Shirine Mohamed
    • 1
    • 6
  • Pierre-Yves Marie
    • 5
    • 8
  • Christine Selton-Suty
    • 4
    • 7
  • Denis Wahl
    • 1
    • 2
    • 3
    • 6
  1. 1.Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune DiseasesCentre Hospitalier Universitaire (CHU) NancyNancyFrance
  2. 2.Institut National de la Santé et de la Recherche Médicale (INSERM)NancyFrance
  3. 3.Université de LorraineNancyFrance
  4. 4.Cardiology DepartementCentre Hospitalier Universitaire (CHU) NancyNancyFrance
  5. 5.Departement of nuclear medicineCentre Hospitalier Universitaire (CHU) NancyNancyFrance
  6. 6.Unité de Médecine VasculaireCentre de Compétences Régional des Maladies Vasculaires Rares et Auto-Immunes, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu, CHU NancyVandoeuvre-lès-Nancy CedexFrance
  7. 7.Département de Cardiologie MédicaleInstitut Lorrain du Coeur et des Vaisseaux Louis Mathieu, CHU Nancy–BraboisVandoeuvre-lès-Nancy CedexFrance
  8. 8.Département médecine nucléaireCHU Nancy–BraboisVandoeuvre-lès-Nancy CedexFrance

Personalised recommendations